Imperial College London spin-out Circassia completes Phase II trials into grass allergy treatment.
Circassia, a life sciences spin-out of Imperial College London, has completed Phase II trials into its hay fever treatment.
The UK-based company found that its grass allergy treatment for hay fever sufferers delivered significantly improved allergy symptoms over the pollen period, compared to a control group on placebos.
The life sciences firm, which also developing treatments for immune responses to cats and dust mites, has raised £105m ($178m) since founding in 1998. Among its backers are Imperial College London’s tech transfer unit Imperial Innovations (II) with a 20.3% shareholding in Circassia, and Invesco, the majority shareholder in II. Others include investment bank Goldman Sachs, Lansdowne Partners, and Tudor Capital.
Russ Cummings, chief executive of Imperial Innovations, said: “This trial has demonstrated the potential of Circassia’s allergy treatment platform to improve symptoms for seasonal allergies, in addition to those which affect patients all year-round. The broad range of applications for this platform demonstrates the value of the technology which is being developed within Circassia.”
